Published in final edited form as:

Annu Rev Pathol. 2019 January 24; 14: 469–495. doi:10.1146/annurev-pathmechdis-012418-012955.

RNA Binding Proteins and the Pathogenesis of Frontotemporal Lobar Degeneration

Jeffrey W. Hofmann¹, William W. Seeley^{1,2}, Eric J. Huang^{1,3}

¹Department of Pathology, University of California, San Francisco, California 94143, USA

²Department of Neurology, University of California, San Francisco, California 94148, USA

³Pathology Service 113B, Veterans Affairs Medical Center, San Francisco, California 94121, USA

Abstract

Frontotemporal dementia is a group of early onset dementia syndromes linked to underlying frontotemporal lobar degeneration (FTLD) pathology that can be classified based on the formation of abnormal protein aggregates involving tau and two RNA binding proteins, TDP-43 and FUS. Although elucidation of the mechanisms leading to FTLD pathology is in progress, recent advances in genetics and neuropathology indicate that a majority of FTLD cases with proteinopathy involving RNA binding proteins show highly congruent genotype–phenotype correlations. Specifically, recent studies have uncovered the unique properties of the low-complexity domains in RNA binding proteins that can facilitate liquid–liquid phase separation in the formation of membraneless organelles. Furthermore, there is compelling evidence that mutations in FTLD genes lead to dysfunction in diverse cellular pathways that converge on the endolysosomal pathway, autophagy, and neuroinflammation. Together, these results provide key mechanistic insights into the pathogenesis and potential therapeutic targets of FTLD.

Keywords

FTD; frontotemporal dementia; FTLD; frontotemporal lobar degeneration; ALS; amyotrophic lateral sclerosis; RNA binding proteins; TDP-43; FUS; low-complexity domain; hydrogels; liquid droplets

1. INTRODUCTION

Frontotemporal dementia (FTD) refers to a group of dementia syndromes with early age of onset that are linked to underlying frontotemporal lobar degeneration (FTLD) pathology (1, 2). The first description of FTD came from the Czech neurologist Arnold Pick, who described patients suffering from slowly progressive language and behavioral disorders (3, 4). Postmortem neuropathological examination of one of Pick's patients revealed focal atrophy in the anterior temporal lobes, suggesting that dementia can be clinically and

eric.huang2@ucsf.edu.

DISCLOSURE STATEMENT

The authors are not aware of any affiliations, memberships, funding, or financial holdings that might be perceived as affecting the objectivity of this review.

anatomically focal. Using Bielschowsky silver staining methods, Alois Alzheimer identified key microscopic features in the brain of Pick's patient, including silver-positive, or argyrophilic, neuronal cytoplasmic inclusions in affected brain regions (5). These inclusions, now known as Pick bodies, were noted to be different from the neurofibrillary tangles seen in patients with Alzheimer's disease (AD).

Advances in clinical assessment, neuroimaging, human genetics, and neuropathological examinations have transformed our ability to characterize neurodegenerative diseases and explore disease mechanisms. Clinically, FTD can be categorized into six major subtypes, including behavioral variant FTD (6), the semantic variant and the nonfluent/agrammatic variant of primary progressive aphasia (7), frontotemporal dementia–motor neuron disease, and two dementia–movement disorder syndromes, corticobasal syndrome and progressive supranuclear palsy–Richardson syndrome (PSP-RS; also known as Steele–Richardson–Olszewski syndrome) (Figure 1) (8, 9). Clarifying the clinical features of FTD enabled a deeper understanding of the neuroanatomy of each major syndrome. In parallel, the advent of network-sensitive neuroimaging approaches, including task-free functional magnetic resonance imaging and diffusion tensor imaging, has allowed researchers to make new maps describing the topology of human brain networks. Increasingly, these converging data streams have revealed that each FTD syndrome reflects the degeneration of a specific large-scale neural network (10, 11) and connectomic mapping can predict how degeneration will spread throughout brain networks (12, 13).

Another exciting new development in FTD research relates to the potential association between patients with specific subtypes of FTLD pathology and autoimmune disorders. This association was first noted in case–control studies that evaluated the prevalence of autoimmune diseases in control, FTLD, and AD patients. The results showed that certain FTLD patient cohorts, especially those with semantic variant primary progressive aphasia and mutations in the progranulin (*GRN*) and *C9orf72* genes, have a higher rate of nonthyroid autoimmune diseases, such as inflammatory arthritis, cutaneous disorders, and gastrointestinal conditions (14, 15). This association is further strengthened by a recent report that analyzes data from large-scale genome-wide association studies (GWASs) provided by the International FTD-Genomics Consortium. The results identify several immune-associated genetic loci, particularly genes within the *HLA* loci, which increase the risk for FTD (16). Many of these FTD immune genes have been implicated in microglial and macrophage functions. Section 4 provides further discussions on the newly discovered roles of *GRN* and *C9orf72* in microglia and the brain innate immunity system (17, 18).

The unique neural circuit vulnerability and immune dysfunctions in FTLD represent two rapidly developing and interwoven research areas that are pushing the boundaries of understanding these devastating neurodegenerative diseases. In addition, the expansion in knowledge of the genetics of FTLD has further facilitated the understanding of the disease mechanisms. Given the tremendous progress made during the past few years, we feel that this is the right time to provide a review that focuses on the congruent phenotype–genotype correlation between the neuropathology and genetic mutations in FTLD and how genetic mutations implicated in familial FTLD provide instructive information for guiding research into the molecular and cell biological bases of FTLD in general. Our discussion focuses on

the unique properties of the low-complexity (LC) domain of RNA binding proteins and its contribution to liquid–liquid phase separation (LLPS) in the formation of membraneless organelles. We also discuss how mutations in FTLN genes lead to dysfunction in diverse cellular pathways that converge on RNA binding proteins, most notably FUS and TARDBP (TAR DNA binding protein 43 kDa, or TDP-43), and ultimately contribute to disease pathogenesis.

2. THE PATHOLOGY, GENETICS, AND CELL BIOLOGY OF FTLN

2.1. Proteinopathy in FTLN

The FTD syndromes are united by their association with underlying FTLN pathology, although AD pathology contributes in a small but important minority of patients whose clinical presentations mimic FTD (Figure 1). From a neuropathological perspective, FTLN can be divided into three major molecular classes: FTLN-tau, FTLN-TDP, and FTLN-FUS; each of these features distinct subtypes based on the morphology and distribution of disease-associated protein inclusions (Figure 2) (19, 20). As highlighted in Figure 2a, patients with Pick's disease develop tau protein aggregates that predominantly contain three microtubule binding repeats (3R tau) in the Pick bodies, whereas patients with progressive supranuclear palsy or corticobasal degeneration develop tau aggregates with four repeats (4R tau) in thorny astrocytes or tufted astrocytes (Figure 2b,c). In addition, tau proteinopathy can be detected in familial FTD with mutations on the *MAPT* gene on chromosome 17. Other forms of tau proteinopathy have been described, including chronic traumatic encephalopathy (21), argyrophilic grain disease (22), globular glial tauopathy, and others (23).

Although FTLN-tau was the first molecular class discovered, FTLN-TDP is the most frequent class, accounting for more than half of most large series. Indeed, the discovery of TDP-43 as the other major disease protein in FTLN and as the dominant aggregating disease protein in amyotrophic lateral sclerosis (ALS) provided a major breakthrough for research into neurodegenerative diseases (24, 25). Furthermore, TDP-43 inclusions can be observed in patients with AD and as part of cognitively normal aging, suggesting that the abnormal formation of TDP-43 protein aggregates may have broader implications (26, 27). Following the identification of TDP-43 as a major disease protein, two genetic discoveries provided important insights into the pathogenesis of FTLN-TDP. The first is autosomal dominant mutations in the *GRN* gene, located on chromosome 17q21.31 near the *MAPT* locus (28, 29). The second mutation is the (GGGGCC)_n hexanucleotide repeat expansion (HRE) that is located between exons 1a and 1b of the *C9orf72* gene on chromosome 9p21.2 (30, 31). *C9orf72* mutations are the most common cause of familial and sporadic FTLN and ALS. Importantly, patients with *GRN* or *C9orf72* mutations almost invariably develop abnormal TDP-43 protein aggregates as the major pathological signature.

Based on the laminar distribution, morphology, and subcellular localization of TDP-43 protein aggregates in the cerebral cortex, FTLN-TDP can be classified into four major subtypes, A, B, C, and D (19). FTLN-TDP type A is characterized by numerous short, dystrophic neurites and compact, crescent-shaped or ovoid neuronal cytoplasmic inclusions, predominantly in the upper cortical layers (Figure 2d). Although rare, neuronal intranuclear inclusions can also be detected. In type B, a few to a moderate amount of fine threads or

grains may be present, but the predominant inclusion type is a fine, granulofilamentous or speckled neuronal cytoplasmic inclusion found in the upper and deep cortical layers. More compact, ovoid neuronal cytoplasmic inclusions may also be seen in the same distribution (Figure 2e). FTLT-DTP type C is characterized by its predominant long, swollen dystrophic neurites that are most prominent in the upper cortical layers but also extend into the deeper layers (Figure 2f). These neurites dominate the picture, and few neuronal cytoplasmic inclusions are seen in the cerebral cortex, although compact or round neuronal cytoplasmic inclusions are identified in some subcortical structures, particularly the ventral striatum. Finally, type D is a rare form characterized by numerous short, dystrophic neurites and frequent round or lentiform neuronal intranuclear inclusions. In familial FTLT-DTP, the specific gene mutation strongly predicts the pathological subtype. FTLT with a *GRN* mutation is accompanied by type A pathology, whereas most patients with *C9orf72* mutations develop type B or, less often, type A or a TDP-43 proteinopathy that is too sparse or atypical to classify. In addition, early reports suggested that patients with mutations in *TIA1* (T cell-restricted intracellular antigen 1) develop type B (32, 33), whereas those with mutations in the *TBK1* (TANK binding kinase 1) gene may develop either type A or B (Figure 1) (34–36). Finally, mutations in the *VCP* (valosin-containing protein) gene, which is a member of the AAA-ATPase gene superfamily, are identified in the rare patients with FTD associated with inclusion body myositis and Paget’s disease of bone. These patients universally develop type D, which is not seen in other genetic or sporadic cases (37).

Once FTLT cohorts had been sorted into patients with FTLT-tau and those with FTLT-DTP, there remained 5–10% in most large series in whom ubiquitin-positive, tau- and TDP-43-negative inclusions were seen; the most common subtype among this group was termed atypical FTLT-ubiquitin (aFTLT-U). Three years after the discovery of TDP-43 as a major insoluble protein in FTLT patients, mutations in the *FUS* (*TLS*) [fused in sarcoma (translocated in liposarcoma)] gene were shown to cause familial ALS, and FUS protein-containing inclusions were identified in these patients (Figure 2g–i) (38, 39). The link between FTLT and ALS then helped catalyze the discovery that aFTLT-U is characterized by inclusions containing FUS, the protein product of *FUS* (*TLS*) (Figure 2j) (40, 41). Further work showed that the inclusions in this and other non-tau, non-TDP-43 FTLT subtypes—including neuronal intermediate filament inclusion disease and basophilic inclusion body disease—contained FUS protein as well as the other proteins from the FET family, including EWS (Ewing sarcoma) protein and TAF15 (TATA-box binding protein associated factor 15).

Due to mutations in *FUS*, in ALS-FUS the characteristic neuropathological features include well-delineated single or multilobulated basophilic inclusions in the cytoplasm of spinal motor neurons, neurons in the brainstem nuclei, and cortical neurons. These inclusions are strongly immunoreactive for FUS protein (Figure 2g), but the levels of ubiquitin in these inclusions vary. Interestingly, these inclusions contain only FUS and not other FET family proteins (40). Ultrastructurally, these inclusions contain abundant filamentous protein aggregates that are immunoreactive for FUS (Figure 2h,i) (42). These filamentous FUS-positive structures, measuring 15–20 nm in diameter, are intermixed with disorganized intracellular organelles, including the endoplasmic reticulum, mitochondria, and lipid droplets, suggesting that the formation of these inclusions may interfere with the normal

functions of these organelles. FTLN-FUS pathology varies by subtype, but in aFTLD-U the inclusions include characteristic serpentine or vermiform neuronal intranuclear inclusions and compact or ovoid neuronal cytoplasmic inclusions (Figure 2j). Curiously, unlike ALS-FUS, which is always the result of a *FUS* mutation, genetic analyses in most FTLN-FUS patients show no evidence of mutations in the *FUS* gene. Most patients with FTLN-FUS present with behavioral variant FTD or FTD-motor neuron disease and tend to be younger and have a more rapidly progressive clinical course, with extreme anterior striatal atrophy as well as atrophy in typical FTD-related cortical areas (43).

2.2. The Genetics of FTLN

The idea that FTD and ALS are on a disease spectrum is further supported by evidence that patients with familial FTD and ALS often share mutations in the same genes. A variety of genetic mutations have been found to cause familial FTD, including the three most common FTLN disease genes, *MAPT*, *GRN*, and the (GGGGCC)_n HRE in the *C9orf72* gene (44). In addition, rare FTLN disease-associated genes include *CHMP2B* (charged multivesicular body protein 2B), *VCP*, *hnRNPA1* (heterogeneous nuclear ribonucleoprotein A1), *hnRNPA2B1* (heterogeneous nuclear ribonucleoprotein A2/B1), *SQSTM1* (sequestosome 1; p62), *TBK1*, *OPTN* (optineurin), *TARDBP*, *FUS*, *TIA1*, *CHCHD10* (coiled-coil-helix-coiled-coil-helix domain containing 10), *UBQLN2* (ubiquilin 2), and *DCTN1* (dynactin 1). Finally, mutations in *CSF1R* (colony stimulating factor 1 receptor), *TREM2* (triggering receptor expressed on myeloid cells 2), and *PRKAR1B* (protein kinase cAMP-dependent type I regulatory subunit beta) have been identified in FTLN patients with atypical clinical presentations. Intriguingly, several of these FTLN genes—most notably the *C9orf72* HRE, *TARDBP*, and *FUS*—are also identified in patients with sporadic and familial ALS, again supporting the idea of a disease spectrum containing FTD and ALS. Unlike for AD, relatively few FTLN genetic risk factors have been identified in GWASs. To date, the most replicated FTLN risk gene is *TMEM106B* (transmembrane protein 106B), especially in patients with *GRN* or *C9orf72* mutations (44). Based on the studies described in Reference 44, carriers of the T allele on a single nucleotide polymorphism (rs1990622) in *TMEM106B* show increased risk for FTLN, whereas the C allele appears to be protective. Other genes implicated in increasing the risk for FTLN include the *HLA* locus on chromosome 6p21.3, *RAB38* on chromosome 6p21.3, and *CTSC* (cathepsin C).

2.3. Cellular Pathways Targeted by FTLN

The highly significant genotype-phenotype association between genetic mutations and TDP-43 proteinopathy (Figure 1) strongly suggests that further investigations into the functions of these FTLN genes should provide critical insights into disease pathogenesis. Here, we summarize several themes that have emerged about the key cell biological pathways that are affected by the FTLN genes. The first major theme indicates that dysfunction and protein misfolding in RNA binding proteins are prominent features of FTLN, as highlighted by pathology and genetics. Several FTLN mutations are identified in genes that encode RNA binding proteins, such as *TARDBP*, *hnRNPA1*, and *hnRNPA2B1*. In particular, TDP-43 is a major nuclear protein that regulates many important aspects of RNA metabolism, including RNA splicing, transcription, and nuclear-cytoplasmic transport (45–48). Similar to TDP-43, FUS also has broad and critical functions in RNA splicing, RNA

transport, DNA damage repair, and the assembly of nucleoli, nuclear speckles, and stress granules (41, 48).

The second theme is the assembly and disassembly of RNA binding proteins and RNA granules. As is discussed in more detail in Section 3, a large number of recent studies provide exciting evidence that RNA binding proteins possess the unique properties of the LC domains that promote the formation of membraneless organelles. These properties can be interfered with by two major products made by the (GGGGCC)_n HRE mutations in the *C9orf72* gene, namely the RNA foci and dipeptide repeat (DPR) proteins (30, 31, 48).

Finally, a majority of FTLN genes—including *GRN*, *C9orf72*, *VCP*, *OPTN*, *CHMP2B*, and *SQSTM1*—are involved in vesicular trafficking in the endolysosomal pathway, autophagy and the formation of the autophagosome, and the protein quality control process. There is compelling evidence from animal models and human pathology that many of these genes regulate these cellular pathways in a gene dose-dependent manner. Given the broader roles of these pathways in diverse cell types, it is conceivable that mutations that interfere with the normal functions of these genes can trigger chain reactions with devastating consequences.

In Section 3, we discuss in depth the discovery of the LC properties of RNA binding proteins and how these unique properties offer new insights into the fundamental disease mechanisms of FTLN. In Section 4, we use the two most common FTLN mutations, of *C9orf72* and *GRN*, to highlight how dysfunctions in the endolysosomal and autophagy pathways may facilitate the formation of TDP-43 proteinopathy. In addition, we discuss how mutations in *SQSTM1*, *UBQLN2*, *OPTN*, and *VCP* could negatively impact the autophagy pathway. Finally, we discuss the newly revealed and exciting roles of *GRN* and *C9orf72* in neuroinflammation and how this phenotype may contribute to neurodegeneration and dysfunctions in the immune system in subsets of FTLN patients.

3. LOW-COMPLEXITY DOMAINS IN RNA BINDING PROTEINS

3.1. Low-Complexity Properties of FUS

Through serendipity, a series of studies has uncovered a unique structural and biochemical property that underscores the aggregation-prone nature of FUS (49). Using biotinylated isoxazole (b-isox)—a synthetic organic chemical that promotes neuronal fate in embryonic stem cells (50)—McKnight and colleagues (51, 52) isolated hundreds of proteins that form spontaneous precipitates with b-isox, presumably due to the increased propensity of b-isox to crystallize into orderly structures that resemble extended β strands in proteins. Mass spectrometry shows that the majority of the proteins in the precipitates with b-isox are RNA binding proteins that possess highly homologous LC domains—of about 200 amino acids in length—to provide the interaction interface with b-isox. The three proteins with the highest affinity for precipitating with b-isox are the RNA binding proteins FUS, EWSR1 (EWS RNA binding protein 1), and TAF15, which are collectively known as the FET proteins, given their close homology in amino acid sequences. A series of biochemical assays further revealed two properties in the FUS LC domain. First, when purified as a fusion protein with green fluorescent protein, maltose binding protein, or glutathione *S*-transferase, the FUS LC domain can self-assemble into amyloid-like polymers via homotypic interactions. This

allows the FUS LC domain to undergo physical phase transition from soluble proteins into gel-like structures called hydrogels (51, 52). Second, a simple binding assay, which involves trapping these hydrogels, allows visualization of FUS and other LC domain-containing proteins under microscopy. This assay has been instrumental in characterizing the LC domain in other RNA binding proteins in the b-isox precipitates and identifying other potential binding partners for the FUS LC domain via heterotopic interactions. One salient example is the identification of the C-terminal domain (CTD) of RNA polymerase II as a binding partner for the LC domain of FET proteins (53). The CTD of mammalian RNA polymerase II—which contains 52 repeats of almost exclusively 4 amino acids, tyrosine, serine, proline, and threonine—is by definition an LC domain itself. Intriguingly, the CTD does not self-assemble into amyloid-like polymers, but it can bind to hydrogels formed by the LC domain of the FET proteins. The polymer formation between the FUS LC domain and the CTD can be regulated by cyclin-dependent kinase-mediated phosphorylation of the CTD. These results have been independently validated using a conventional protein purification scheme to identify FUS interacting partners (54, 55). In addition to the CTD of RNA polymerase II, several serine:arginine repeat domain-containing proteins implicated in pre-mRNA splicing are also identified in the b-isox precipitates. Similar to the CTD, the serine:arginine domains of these splicing factors do not self-assemble, but they can be readily detected in FUS LC domain hydrogels and then reversed upon phosphorylation by cyclin-dependent kinases.

Despite the compelling evidence supporting the unique hydrogel properties of the FUS LC domain, several studies offer a different interpretation regarding its biophysical properties. In a study designed to investigate the assembly of multivalent macromolecules, Rosen and colleagues (56) discovered that when the SRC homology 3 (SH3) domain and its proline-rich motif (PRM) ligand are organized in tandem repeats, they exhibit phase separation properties to form liquid-like droplets (a process also known as LLPS). Structural analyses show that these droplets do not represent aberrant aggregate formation, but rather they are the result of a highly ordered and thermodynamically coupled molecular sol–gel transition within the droplet phase. Such behavior of SH3_n and PRM_n repeats can be detected in live cells and in other signaling molecules, such as the nephrin/NCK/N-WASP system (56). Following the publication of the study, a series of papers showed that the LC domains in many RNA binding proteins—such as FUS, hnRNPA1, Lsm4 (involved in P-body assembly in yeast), and stress granule protein TIA1 and its yeast homolog Pub1—are intrinsically disordered and can undergo LLPS (Figure 3) (57–60). The formation of liquid droplets from the LC domains of these proteins shows progressive maturation over time, and this is further supported by the presence of RNA. Similar to the reported heterotypic interactions of the FUS LC domain with other RNA binding proteins in hydrogels, in liquid droplets it can recruit additional LC domains from other RNA binding proteins. Most impressively, disease-related mutations in FUS and hnRNPA1 LLPS can promote solid-state or fibrillary transformation (57, 58). Together, these results provide key mechanistic insights into how the unique biophysical properties of LC domains in FUS and hnRNPA1 are pathogenic in neurodegeneration (Figure 3).

While data about both the hydrogels and liquid droplets highlight the unique properties of the FUS LC domain to undergo reversible liquid-to-solid phase transition, there are some

fundamental differences regarding the nature of protein–protein interactions between these two physical states. Structural studies of the hydrogels indicate that the interactions of the LC domains of FET proteins and the CTD form cross- β polymers, which are a key characteristic in many yeast proteins with prion-like properties (61). Data from electron microscopy and nuclear magnetic resonance spectroscopy further reveal that the FUS LC domain polymers structurally resemble other pathologically aggregated proteins, such as the A β 40 and A β 42 amyloid peptides seen in AD. However, unlike A β 40, A β 42, and α -synuclein, the FUS LC domain lacks hydrophobic amino acids that provide a hydrophobic protein interaction interface to promote the formation of pathogenic prion-like polymers. In addition, FUS LC domains can be phosphorylated by DNA-dependent protein kinase, which promotes the dissolution of FUS nuclear puncta and the translocation of FUS from the nucleus to the cytoplasm (62–64). Indeed, contrary to the cross- β polymer model, solution nuclear magnetic resonance assays combined with photobleaching show that the FUS LC domain is intrinsically disordered, both as a monomer and within the liquid droplet state (59, 60). One significant physical property of the FUS LC domain liquid droplets is that the degenerate tyrosine and glutamine residues in the repeats provide high-valency, hydrophobic, but not electrostatic, interactions that stabilize FUS LC phase separation. Such formation of liquid droplets can be further promoted by the presence of RNA, low temperatures, and low salt (59). While the exact cause or causes accounting for the differences in the biophysical properties of hydrogels and liquid droplets remain unclear, these unique properties of FUS LC domains have tremendous impacts on the biological functions of nuclear compartmentalization, RNA granule formation, and the biogenesis of intracellular organelles (65–67).

3.2. The FUS Low-Complexity Domain and RNA Granule Assembly

The discovery of the unique biophysical properties of the FUS LC domain in hydrogels or LLPS opens up multiple lines of investigation into the broader role of RNA binding proteins, such as FUS, hnRNPA1, and TDP-43, in the assembly of RNA granules and whether perturbations to this process may contribute to the pathogenesis of FTD and ALS. RNA granules are membraneless structures that control mRNA translation, localization, transport, and degradation in eukaryotes (68). The involvement of FUS in RNA granules was first implicated in a study that aimed to identify the role of conventional kinesin (KIF5) in the transportation of RNA granules along dendrites in neurons (69). Among the 42 proteins in the RNA granules fully characterized by mass spectrometry in the study, FUS shared similar elution profiles on KIF5 affinity chromatography with several RNA binding proteins, including DDX3 (DEAD-box polypeptide 3, an RNA helicase), SYNCRIP (synaptotagmin binding cytoplasmic RNA interacting protein, a multifunctional heterogeneous ribonucleoprotein), several FMRPs (fragile X mental retardation proteins), and ALY (a transcriptional coactivator and nuclear export factor). These results suggest that FUS may be involved in multiple steps in the formation of RNA granules, from nuclear–cytoplasmic transport to assembly and local protein translation. Consistent with these results, the majority of FUS proteins are present in the nuclear fractions, although a significant amount can also be detected in the cytoplasm. The localization of FUS to RNA granules seems to be disrupted by ribonuclease treatment, suggesting that the presence of FUS in these granules may depend on its binding to RNA.

If the KIF5 study provides a glimpse of the potential roles of FUS in RNA granule biology, the identification of the unique properties of the FUS LC domain opens up tremendous opportunities to interrogate its interactomes and in vivo functions under physiological conditions. One remarkable finding from the mass spectrometry analyses of the b-isox precipitates is that the majority of the proteins are involved in neuronal RNA granules, stress granules, processing bodies, or polar granules (52). Intriguingly, there is extensive overlap between the protein constituents in the KIF5 RNA granules and b-isox precipitates, supporting a critical role for the FUS LC domain in the assembly and functions of RNA granules. Indeed, FUS LC domain hydrogels have been used to isolate and characterize bound and unbound RNAs from mouse brain lysates. Deep sequencing revealed 11 mRNAs that are enriched in the RNA granules in the neuronal dendrites that are critical for dendritic growth and synaptic functions (51). These results support the idea that the FUS LC domain may regulate the assembly of RNA granules. In support of this, fluorescently tagged bacteriophage MS2 stem-loop RNAs can bind to FUS LC domain hydrogels. Furthermore, FUS has also been shown to form high-order RNA–protein complexes with other RNAs that have stem-loop structures. Several studies report similar binding of FUS to stem-loop RNA structures (70, 71) or to the secondary and tertiary structures formed by the short RNA repeats r(UUAGGG) in the G-quadruplex telomeric repeat-containing RNA (or TERRA) (72).

3.3. FUS Mutations and Proteinopathy

The above-referenced studies establish several key insights regarding the general principles employed by FUS and other RNA binding proteins in regulating the assembly of RNA granules and other membraneless structures. First, the FUS LC domain is structurally disordered and can form a hydrogel or LLPS state, which provides a versatile protein–protein or protein–RNA interaction interface that has a critical role in RNA granule assembly. These interactions are tightly regulated by phosphorylation on serine residues in the LC domain, suggesting that the FUS LC domain has an active role in the assembly and disassembly of the constituents of the RNA granules. Second, the hydrogel or LLPS properties of the LC domain in FUS and other RNA binding proteins have broader implications for the spatiotemporal control of signal transduction and the partitioning of subcellular compartments in the nucleus and cytoplasm. Finally, the dynamic progression of the FUS LC domain from LLPS to liquid droplets to the formation of spike-like fibers raises the possibility that disease-causing mutations in FUS and other RNA binding proteins, such as hnRNPA1 and TDP-43, may directly contribute to abnormal protein aggregation and cellular pathology in FTD and ALS. In support of this idea, liquid droplets that include the FUS LC domain that carries an ALS-related point mutation, FUS G165E, show a significant decrease in their ability to fuse with other liquid droplets and an increased propensity to convert from droplets to fibrous structures (58). Consistent with these results, ALS-related mutations in the CTD of FUS—including FUS R495X, FUS R522G, FUS R524S, and FUS P525L—also show reduced reversibility in liquid droplet assembly and disassembly, which correlates with an increased propensity to form protein aggregates and increased neurotoxicity when these proteins are expressed in *Caenorhabditis elegans* (73). Interestingly, small interfering RNA knockdown of stress granule components partially rescues the neurotoxicity, suggesting that mutant FUS protein aggregates may dominantly

sequester RNP granule formation (Figure 3). Similar to FUS mutations, missense mutations in the LC domain of hnRNPA1, which are causally linked to the neurodegenerative diseases ALS and multisystem proteinopathy (74), also promote fibrillization in hnRNPA1 (57).

Taken together, these results support the model of the LC domains of RNA binding proteins providing multivalent interfaces that promote hydrogel formation or LLPS phase transition that are critical for reversible assembly and disassembly of membraneless structures, such as nuclear bodies, speckles, RNP granules, and stress granules (Figure 3). These structures critically regulate diverse cellular physiology, including the DNA damage response, RNA splicing, RNA transport, and protein synthesis. Most importantly, the discovery of the unique biophysical properties of the FUS LC domain provides critical mechanistic insights into understanding the pathological features of FUS protein aggregates in ALS-FUS and FTL-D-FUS. Disease-related mutations in *FUS* or other pathological conditions alter the multiphase characteristics and the metastability of these RNP granules, leading to irreversible protein aggregations and devastating pathology in vulnerable neurons.

4. PATHWAYS LEADING TO FTL-D-TDP

4.1. *C9orf72* Mutations

The identification of HRE mutations in the *C9orf72* gene in FTD patients has captured tremendous attention because of the high prevalence of these mutations in familial FTD cases. It is increasingly clear that *C9orf72* mutation carriers in the same family can present with diverse clinical presentations, underscoring the complexity of the pathogenesis caused by this mutation. Here, we summarize several key features that can potentially contribute to the mechanisms of disease in patients with *C9orf72* mutations.

4.1.1. RNA foci and repeat-associated non-ATG-mediated protein translation.

—At the outset of the discovery of *C9orf72* HRE mutations, it was reported that the sense transcripts of the (GGGGCC)_n repeats can be detected in the nuclei of cortical neurons and spinal motor neurons in postmortem tissues from patients with *C9orf72* mutations, but not in other ALS or FTD patients (30). Since similar repeat-associated transcripts have been reported in other noncoding repeat expansion diseases—such as myotonic dystrophy, fragile X-associated tremor/ataxia syndrome, and spinocerebellar ataxias (75)—these RNA foci garnered immediate attention as the potential pathogenic factor in the neurodegeneration associated with *C9orf72* mutations. Indeed, similar RNA foci can be detected in neurons derived from induced pluripotent stem cells (iPSCs) from patients with *C9orf72* mutations (76–78) and in neurons in transgenic mice that express bacterial artificial chromosome (BAC) isolated from patients with *C9orf72* mutations (79–82). The foci of the antisense transcript, composed of (CCCCGG)_n repeats, are also detected, indicating that bidirectional transcription occurs at the *C9orf72* HRE (83).

One mechanism by which HRE RNA may aggregate into foci is by the formation of G-quadruplexes, in which four guanine bases interact around a central cation, often potassium, to form a planar structure, called a guanine tetrad, in a process known as Hoogsteen bonding, and multiple tetrads can stack to form a G-quadruplex. This is a physiologic mechanism of transcriptional and translational regulation and protection of telomere ends.

(GGGGCC)_n repeats form extremely stable, multimolecular G-quadruplexes that incorporate multiple strands of RNA, and they are more readily formed with increased repeat length and concentration (84). Presumably, the accumulation of these (GGGGCC)_n-containing RNA foci near the nucleoli can have toxic gain-of-function properties that interact with RNA binding proteins and interfere with gene expression (76, 77). In addition to the formation of RNA foci, (GGGGCC)_n repeats can also form DNA–RNA hybrids and G-quadruplexes that further promote the sequestration of RNA binding proteins (76, 85) and interfere with the machinery that regulates the nuclear–cytoplasmic transport pathway (86, 87).

Another major discovery related to *C9orf72* mutations is that the (GGGGCC)_n-containing RNA might be aberrantly translated into DPR proteins from both sense and antisense orientations—including poly(glycine–alanine) (GA), poly(glycine–proline) (GP), poly(glycine–arginine) (GR), poly(proline–alanine) (PA), and poly(proline–arginine) (PR)—via repeat-associated non-ATG-mediated (or RAN) translation (88, 89). As predicted, all DPR proteins can be detected in the neurons of the cerebral cortex, cerebellum, hippocampus, thalamus, and several other brain regions in patients with *C9orf72* mutations, in neurons derived from *C9orf72* iPSCs, and in *C9orf72* BAC transgenic mouse models. These DPR proteins are reported in neurons, but not in glia, and are most frequently located in SQSTM1-positive structures immediately adjacent to the nucleus.

Several animal models have been developed to characterize the potential impacts of *C9orf72* DPR proteins. In *Drosophila*, the expression of arginine-containing GR and PR causes robust degenerative phenotypes in the eyes, whereas the expression of GA and PA shows no effects (90). Although DPR proteins can also be detected in *C9orf72* BAC transgenic mice, the neurodegenerative phenotypes in these models have been variable, perhaps due to the low expression levels (79–82). Using the adeno-associated virus (AAV2)–based approach, Petrucelli and colleagues (91) showed that intraventricular delivery of AAV2 (GGGGCC)₆₆ produces a robust expression of RNA foci and DPR proteins—including GR, GP, and GA—in neurons in the cerebral cortex, hippocampus, cerebellum, and spinal cord. In addition, ~7–8% of DPR-containing neurons show phosphorylated TDP-43-positive inclusions. Mice injected with AAV2 (GGGGCC)₆₆ show evidence of neuronal loss in the cerebral cortex and exhibit behavioral phenotypes, including hyperactivity and motor coordination deficits.

4.1.2. Dipeptide repeat proteins and RNA binding proteins.—Since the discovery of DPR proteins associated with *C9orf72* mutations, there have been many reports validating the presence of these proteins in postmortem brain tissue from these patients. The ongoing debates, however, are whether the distribution of DPR proteins correlates with TDP-43 proteinopathy in the same patient; why there is a paucity of DPR proteins in the spinal motor neurons of patients with *C9orf72* mutations, even in those who present with ALS; and how DPR proteins could interfere with cellular functions and ultimately contribute to neurodegeneration. While it might take more time to resolve all of these issues, several recent studies provide critical insights into these questions. In a study that investigates the clinical, neuroimaging, and neuropathological features of two FTD patients with *C9orf72* mutations that illuminate these issues, Seeley and colleagues (92) show that RNA foci and DPR proteins are present before symptom onset and these features can be detected before TDP-43 proteinopathy is fully developed and also in the absence of it. These results suggest

that *C9orf72*-associated molecular changes, including the development of RNA foci and DPR proteins, may impact brain function and structure before symptom onset and also impact the formation of TDP-43 protein aggregates.

Indeed, several studies have uncovered surprising properties of DPR proteins and their potential interactions with RNA binding proteins, lending critical mechanistic insights into these interesting pathological observations in *C9orf72*-mutation-associated FTL. The first evidence comes from a study showing that the DPR proteins GR_n and PR_n can interact with the hnRNP A1 hydrogel in manners similar to serine-arginine-rich pre-mRNA splicing factors (93). Remarkably, the DPR proteins GR_n and PR_n can be taken up by cells and translocated to the nucleus where they interact with nucleoli and interfere with pre-mRNA splicing, including the splicing of *EAAT2* (excitatory amino acid transporter 2), which has been previously reported to be downregulated in ALS disease models. Two independent studies reveal the unique properties of GR_n and PR_n in interacting with the LC domains of many of the RNA binding proteins implicated in LLPS using assays that involve either hydrogels or liquid droplets. The DPR interactomes include proteins involved in the organization of the nuclear pore complex, nucleolus, nuclear speckles, and stress granules (94, 95). The presence of DPR proteins increases the propensity to form filamentous aggregates and interferes with the assembly of stress granules and protein translation. Taken together, these results support the idea that DPR proteins with GR_n or PR_n repeats possess toxic gain-of-function properties that can have negative impacts on several fundamental cellular functions, including the assembly of the intranuclear structure, nuclear–cytoplasmic transport machinery, and stress granule formation (Figure 4).

4.1.3. Cell biology of the *C9orf72* protein.—The position of (GGGGCC)_n repeats in the 5 regulatory region (between noncoding exons 1a and 1b) of the *C9orf72* gene raises the possibility that the insertion of these repeats may affect the expression of *C9orf72* mRNA and protein levels. In support of this idea, there is evidence of hypermethylation in the CpG islands 5' to the repeats and within the repeats (96–98), which correlates with the repeat size and age of onset for disease. Although it remains unclear how hypermethylation could impact *C9orf72* protein levels, results from several studies indicate that *C9orf72* expression is reduced in brain tissues and lymphoblasts from patients with *C9orf72* mutations and that *C9orf72* proteins may have important functions in regulating vesicular trafficking in the endolysosomal and autophagy pathways. For instance, bioinformatics predicts that the *C9orf72* protein contains an amino acid sequence that is homologous to the DENN (differentially expressed in normal and neoplastic cells) domain, which is highly conserved among members of the Rab GEF (guanine nucleotide exchange factor) family (99). The mechanistic insights into *C9orf72* proteins come from several studies, which independently characterize *C9orf72* interactomes and show that *C9orf72* can indeed form a stable multiprotein complex with proteins that are implicated in autophagy and lysosomal pathways, including SMCR8 (Smith–Magenis syndrome chromosome region, candidate 8), WDR41 (WD repeat domain 41), and ATG101 (autophagy related 101) (100–103). Several models have been proposed for *C9orf72* functions. First, the *C9orf72*–WDR41–SMCR8 complex may serve as a GEF that regulates the activity of the small GTPases Rab8a and Rab39b, which are involved in membrane trafficking and the initiation of autophagy (Figure

4). Second, C9orf72 can be detected in the lysosomes where it regulates the activity of the mTOR (mechanistic target of rapamycin) complex and lysosomal morphology. Although the exact role of C9orf72 requires further investigation, it is clear that the loss of C9orf72 enhances autophagic flux and leads to prominent lysosomal defects.

4.1.4. C9orf72 loss of function and neuroinflammation.—One surprising role of C9orf72 comes from the analysis of mice that have homozygous deletion of *C9orf72* (*C9orf72*^{−/−}). While *C9orf72*^{−/−} mice initially showed no evidence of neurodegeneration, these mutant mice developed age-dependent lymphadenopathy and splenomegaly due to macrophage infiltration and the mis-regulation of genes in the inflammation-lysosome-phagosome formation-, ribosome-, and amino acid-metabolism pathways (103–105). Consistent with these results, abnormal lysosomes are reported in C9orf72-deficient macrophages and microglia, although the functional consequences for the latter cell type remain to be determined. In at least one study, *C9orf72*^{−/−} mice exhibited features of severe autoimmune dysfunction, leading to early mortality (104). Unlike in rodents, knocking down *C9orf72* in zebrafish leads to axonal and motor neuron pathologies that synergize with Ataxin-2 that has intermediate polyQ repeats (101, 106). Collectively, these studies uncover the critical roles of C9orf72 proteins in regulating membrane trafficking in the autophagy and lysosomal pathways, which can profoundly impact the physiological functions of neurons and immune cells. It is conceivable that these membrane trafficking defects caused by C9orf72 deficiency may synergize with RNA foci and DPR proteins to promote pathology in patients with *C9orf72* mutations.

4.2. GRN Mutations

Although they were initially isolated as growth factors that regulate tumorigenesis and angiogenesis, recently identified dominant mutations in the *GRN* gene of familial FTD patients herald many new directions to understanding the in vivo function of progranulin during the aging process in the brain. Many new discoveries challenge the conventional view of progranulin as a secreted growth factor. Instead, these results uncover previously unrecognized roles of progranulin in intracellular vesicular trafficking, lysosomal biogenesis, and neuroinflammation.

4.2.1. Cell biology of progranulin.—As described in the previous sections, dominant mutations in the human *GRN* gene constitute a major genetic underpinning of FTD (28, 29). Pathologically, *GRN* mutations invariably lead to aberrant TDP-43 protein aggregates that have a characteristic distribution in the superficial layers of the cerebral cortex (FTLD-TDP type A) (Figure 2) (19, 107). This tight association between *GRN* mutations and TDP-43 proteinopathy raises the intriguing hypothesis that progranulin (PGRN) deficiency can impact fundamental cell biological processes that contribute to the aberrant formation of TDP-43 aggregates. Consistent with this idea, several lines of evidence indicate that PGRN regulates vesicular trafficking in the endolysosomal pathway and the biogenesis of autophagosomes. First, in addition to its role as a secreted factor that promotes vasculogenesis, tumorigenesis, and neurite outgrowth, several studies indicate that secreted PGRN can interact with sortilin and undergo endocytosis from endosomes to lysosomes, where it may be cleaved or degraded to maintain a balanced level of PGRN and granulins

(108–110). Another alternative, and perhaps more efficient and plausible, route for PGRN to regulate the endolysosomal pathway is that following its synthesis in the Golgi apparatus, PGRN may be directly trafficked to the endosomes and then ultimately reach the lysosomes (Figure 4) (17). In support of this model, a proteomic screen identified prosaposin (PSAP) as a key component in the PGRN interactome (111). In addition, a GWAS identified the human *PSAP* gene as a genetic locus that regulates PGRN plasma levels (112). Like PGRN, PSAP can undergo proteolytic cleavage to release cysteine-rich peptides called saposins, which promote sphingolipid hydrolysis and lysosomal functions (113–115). PSAP forms a heterodimer with PGRN and regulates both intracellular and secreted PGRN levels. In addition, PSAP interacts with M6PR (mannose 6-phosphate receptor) or LRP1 (low-density lipoprotein receptor-related protein 1) and facilitates the trafficking of PGRN to the lysosomes (Figure 4). The cooperative role of PGRN and PSAP in lysosomal targeting supports the notion that both have critical roles in regulating lysosomal functions.

While the exact role of PGRN in lysosomal functions remains unclear, there is strong evidence that PGRN deficiency causes severe lysosomal defects in a dose-dependent manner. Individuals with two *GRN* mutant alleles completely lack PGRN and develop a form of lysosomal storage disease known as neuronal ceroid lipofuscinosis (NCL, or ceroid neuronal lipofuscinosis 11) (116). These patients have no detectable PGRN in their plasma and between the ages of 20 and 30 years develop neurological deficits, such as vision loss, myoclonus seizure, and cerebellar ataxia (117, 118). Skin biopsy samples from these patients reveal lipofuscin accumulation, supporting the diagnosis of NCL (116). Remarkably, several studies show that cortical neurons and lymphoblasts from FTLN patients with *GRN* mutations also contain a marked increase in lysosomal storage materials (119, 120). Consistent with the human pathology, *Grn* knockout (*Grn*^{−/−}) mice show an age-dependent accumulation of lipofuscin in neurons and glia (120–125), which upon ultrastructural analyses contains multilamellar fingerprint profiles or onionskin-like storage materials that are diagnostic for NCL (116). Remarkably, confocal scanning laser ophthalmoscopy reveals that similar lipofuscin accumulation phenotypes can be detected in the retina of *Grn*^{−/−} mice and in both presymptomatic and symptomatic *GRN* mutation carriers (120).

Together, these results lead to several important conclusions regarding the functions of PGRN. First, PGRN has dose-dependent effects in regulating endolysosomal pathways. This is supported by the robust NCL phenotype in *Grn*^{−/−} mice, homozygous *GRN* patients, and FTLN patients with *GRN* mutations, but not in *Grn*^{+/-} mice (126). These results support the idea that a critical threshold of intracellular PGRN is required to maintain a homeostatic balance in the vesicular trafficking from late endosomes to lysosomes and the subsequent degradation or clearance of lysosomal structures. Second, although the exact mechanism of PGRN in the biogenesis and function of lysosomes remains to be determined, given the interaction between PGRN and PSAP, it is tempting to speculate that PGRN and its granulin peptides may cooperatively control sphingolipid hydrolysis and lysosomal functions. In support of this idea, lipidomic mass spectrometry analyses in mouse embryonic fibroblasts and lysosome-enriched organelles from liver show that the loss of PGRN results in the upregulation of polyunsaturated triacylglycerides and a concomitant reduction in diacylglycerides and phosphatidylserines (127). Finally, the NCL phenotype is a robust

disease manifestation of the PGRN deficiency state. The fact that the drusen-like lipofuscin deposits can be detected in the retinas of asymptomatic *GRN* mutation carriers presents a highly efficient, noninvasive approach for detecting disease pathology and monitoring clinical progression.

4.2.2. Lysosomes and TDP-43 proteinopathy.—Although it remains unclear how lysosomal defects caused by PGRN deficiency lead to aberrant formation of TDP-43 protein aggregates, several lines of evidence suggest that defects in lysosomes and their affiliated autophagy pathway can contribute to the formation of TDP-43 protein aggregates. As a major site of macromolecular breakdown and recycling, lysosomes and the tightly associated autophagy machinery are critical for cellular control of proteostasis and the response to nutrient deprivation. In addition, dysfunction in autophagy and lysosomes has been implicated as a key player in the pathogenesis of neurodegenerative diseases (128). For instance, mutations in the Gaucher's disease gene *GBA*, which encodes β -glucocerebrosidase, cause juvenile onset lysosomal storage disease and can increase the risk of Parkinson's disease (129, 130). At least two NCL-associated genes, *CTSD* (cathepsin D) and *ATP13A2*, have been linked to, respectively, AD and Parkinson's disease (131, 132). Although the exact mechanism remains to be determined by which lysosomal defects caused by PGRN deficiency can result in the aberrant formation of TDP-43 protein aggregates, several studies show that TDP-43 has an increased propensity to accumulate in the cytoplasm of cortical neurons in aged *Grn*^{-/-} mice and in mice that have two copies of a common *GRNR493X* (1477C→T) mutation (*Grn*^{R493X}) (119, 123, 133). Intriguingly, direct comparisons between *Grn*^{-/-} and *Ctsd*^{-/-} mouse brains showed the prominent accumulation of a number of lysosomal proteins and increased phosphorylation of TDP-43 (serine 409/410), a key signature of TDP-43 proteinopathy in FTLN (119). In addition, the loss of PGRN leads to the upregulation of several autophagy-related proteins. Since PGRN has not been directly implicated in autophagy, these results suggest that the lysosomal defects in PGRN-deficient cells may indirectly promote the activation of the autophagy pathway, which in turn interferes with the function of the autophagosome in the clearance of TDP-43 in the cytoplasm and ultimately results in the formation of TDP-43 protein aggregates (Figure 4). Alternatively, the persistent accumulation of lysosomal abnormalities in PGRN-deficient cells may impact the unconventional secretory pathway regulated by autophagy and lysosomes (134). However, it remains to be determined how these defects might have differential effects in neurons and glia.

Another lysosome-based mechanism that may potentially promote TDP-43 proteinopathy is that certain cleaved granulins may perturb lysosomal functions and thereby interfere with the degradation of TDP-43. Using the nematode *C. elegans* as a model system, a recent study shows that when granulins are expressed in the absence of full-length PGRN, they can increase TDP-43 levels in neurons and exacerbate its toxicity (110). These results suggest that, as with PSAP and saposins, a delicate balance of PGRN and granulins in lysosomes is crucial to regulate the biogenesis and function of these organelles, which are important in controlling proteostasis. Both the complete lack of PGRN and aberrant or excessive levels of granulins may negatively modulate lysosomal functions. Finally, perhaps in an effort to overcome abnormal lysosomal function, PGRN-deficient cells show activation of mTOR and

TFEB (transcription factor EB), a master regulator of lysosomal genes and biogenesis (135–137). The persistent activation of the mTOR and TFEB pathways is likely to aggravate lysosomal defects in PGRN-deficient cells.

4.2.3. Neuroinflammation and TDP-43 proteinopathy.—While the lysosomal defects in PGRN deficiency can be detected in a wide range of cell types—from lymphoblasts to fibroblasts, neurons, and glia—the functional consequences caused by these defects vary in different cell types. Indeed, one prominent feature in *Grn*^{−/−} mice is the age-dependent defects in the brain's innate immune system. Several studies show that the loss of PGRN causes increased phagocytosis and elevated production of proinflammatory cytokines in microglia and macrophages (122, 123, 138). In young *Grn*^{−/−} mice and microglia-specific *Grn* conditional mutant mice (*Cd11b-Cre;Grn*^{fl/fl}), acute exposure to the neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induces a robust microglial response that promotes the engulfment of injured neurons (122). To investigate the role of microglial activation in the context of neurodegeneration, a recent study carried out transcriptomic analyses of several brain regions from a large cohort of aging *Grn*^{+/+}, *Grn*^{+/-}, and *Grn*^{−/−} mice with the goal of identifying age-dependent, genotype-specific changes in gene expression (139). The results showed an age-dependent upregulation of lysosomal genes and genes related to innate immunity, which upon gene ontological and systems-level analyses revealed extensive functional interactions. Similar transcriptomic signatures of neuroinflammation in *Grn*^{−/−} mice have been independently validated by several groups (125, 127, 140, 141). Collectively, these results are in agreement with the prominent expression of *Grn* mRNA in the microglia, and the results support the idea that PGRN is required to suppress excessive microglial activation in the aging process. Indeed, cell biological characterizations show that *Grn*^{−/−} microglia exhibit increased efficiency in trafficking endocytosed materials from endosomes to lysosomes. In addition, *Grn*^{−/−} microglia produce abundant complement proteins, including C1qa, C1qb, C1qc, and C3, which promote synaptic pruning activity that preferentially targets the ventral thalamus, thus leading to profound dysfunctions in the thalamocortical circuit (139). Consistent with the important role of complement-mediated synaptic pruning (142, 143), the removal of C1qa mitigates the dysfunction in the thalamocortical circuit, alleviates aberrant behavioral phenotypes, and prolongs survival in *Grn*^{−/−}; *C1qa*^{−/−} mice. Similar to the profound neuroinflammation phenotype found in *Grn*^{−/−} mice, postmortem examinations of the frontal cortex in FTLN patients with the *GRN* mutation also showed extensive microglial activation. Furthermore, cerebrospinal fluid samples from these patients showed significantly increased levels of C1qa and C3 that positively correlate with progressive cognitive decline.

The identification of profound microglial activation in *Grn*^{−/−} mice and FTLN patients with *GRN* mutations raises a number of intriguing possibilities about how glial pathology contributes to TDP-43 proteinopathy and neurodegeneration. For example, microglial and astroglial activation are known to be tightly coupled during neuroinflammatory responses. Thus, it is possible that PGRN-deficient microglia could recruit and activate *Grn*^{−/−} astrocytes to promote neuroinflammation via mechanisms similar to the lipopolysaccharide model (141). Alternatively, the loss of PGRN in *Grn*^{−/−} astrocytes may lead to spontaneous aberrant activation independently of *Grn*^{−/−} microglia. Regardless of the mechanism, it is

likely that both *Grn*^{-/-} microglia and astrocytes may have synergistic effects in promoting the neuronal stress that facilitates the accumulation of TDP-43 in intracellular organelles, such as stress granules and lysosomes, and ultimately leads to cytoplasmic aggregation of TDP-43 (Figure 4). Given the remarkably similar lysosomal defects seen in microglia and macrophages lacking PGRN or the gene product of *C9orf72* (105), it is tempting to speculate that aberrant glial pathology may be a shared disease-driving factor in FTLT caused by *GRN* or *C9orf72* mutations.

4.3. Autophagy Defects and TDP-43 Proteinopathy

There is abundant evidence that defects in the autophagy pathway play a central part in ALS-FTD pathogenesis. This is underscored by the variety of autophagy-related genes, including *SQSTM1*, *UBQLN2*, *OPTN*, and *VCP*. Autophagy is a catabolic process by which the cell degrades proteins, macromolecules, and organelles, either because they are damaged or unneeded or because their degradation produces resources that can be used for vital cellular functions during starvation (144). To ensure that only appropriate proteins are degraded, E3 ubiquitin ligases select targets with specific features, such as exposed hydrophobic domains, that indicate improper folding. The human proteome includes hundreds of distinct E3 ubiquitin ligases, which individually are somewhat specific, but together can target a broad range of undesirable molecules. E3 ubiquitin ligases transfer a molecule of ubiquitin from an E2 enzyme to a lysine residue on its specific target. As ubiquitin itself can be ubiquitinated on one of several lysine residues, ubiquitin molecules can be chained together. The polyubiquitin linkage pattern is used to direct the target protein for either proteasomal degradation (often through K48 linkages) or lysosomal degradation via autophagy (often through K63 linkages) (145).

Autophagy begins with the formation of a double-membrane vesicle called a phagophore, which elongates and ultimately wraps around and isolates the portion of the cytoplasm that contains the molecules and organelles that have been selected for degradation (Figure 4). The phagophore will mature into an autophagosome, which will fuse with a lysosome to initiate the degradation of its contents. As the phagophore forms, the soluble protein LC3-I (microtubule-associated protein 1 light chain 3) is conjugated to phosphatidylethanolamine to form LC3-II, which associates with the phagophore membrane. *SQSTM1*, *UBQLN2*, and *OPTN* serve as adaptors (or autophagy receptors), which bind to polyubiquitinated proteins and LC3-II, thus collecting autophagy targets within the autophagosome. *VCP* is involved in autophagosome maturation and fusion with lysosomes (146). Mutations in any of the genes encoding these proteins can cause ALS and FTD, suggesting that autophagy plays a central part in the pathogenesis of these diseases.

Mutations in *OPTN* that cause ALS-FTD include a deletion of exons 13–15 and missense, non-sense, and splicing defect–inducing intronic mutations. These mutations result in reduced mRNA and protein expression of *OPTN* (36). *OPTN* mutations result in TDP-43- and ubiquitin-positive inclusions. One ALS-causing mutation, E478G, lies in the ubiquitin binding domain, suggesting that the inability of *OPTN* to recruit polyubiquitinated proteins to the autophagosome gives rise to ALS (147). Consistent with this observation, wild-type *OPTN* colocalizes with TDP-43 aggregates in a *TARDBP* mutation model of ALS, whereas

*OPTN*E478G has reduced colocalization. Furthermore, the overexpression of wild-type *OPTN* reduces TDP-43 aggregates in this model, and transgenic expression of mutant *OPTN* with an impaired ubiquitin binding domain prevents clearance of aggregates in a dominant negative fashion and reduces overall autophagic flux (148).

UBQLN2 mutant ALS-FTD exhibits striking parallels to *OPTN* mutant disease. *UBQLN2* also can bind to TDP-43 at its CTD and enhances its clearance (149). ALS caused by *UBQLN2* mutation results in inclusions positive for *UBQLN2*, *SQSTM1*, TDP-43, FUS, and *OPTN*. Furthermore, transgenic expression of ALS-associated mutant *UBQLN2* leads to the aggregation of TDP-43 (150), and in rats, expressing mutant *UBQLN2* leads to the formation of aggregates that contain both mutant and wild-type *UBQLN2*, suggesting a dominant negative mechanism (151).

SQSTM1 is found in toxic aggregates in a variety of neurodegenerative diseases, including AD, and Parkinson's and Huntington's diseases. A variety of mutations in *SQSTM1* have been found to cause ALS-FTD, including mutations within several exons, introns, and the promoter. The mutations in coding regions are found in domains that interact with ubiquitin, LC3, or Keap1 (Kelch-like ECH associated protein 1) (152). The nonspecific nature of these mutations is most consistent with a loss-of-function mechanism of disease. Similarly, mutations causing ALS-FTD in *VCP* are also found indiscriminately throughout the gene, also supporting a loss-of-function mechanism. *VCP* mutations result in the accumulation of ubiquitin-positive vesicles and *SQSTM1*, which is consistent with a disruption of autophagy (146). Another more specific effect of *VCP* mutations is impairments in processing stress granules. *VCP* is involved in stress granule clearance by autophagy (153), and *VCP* knockdown in cell culture decreases stress granule formation and alters stress granule morphology and composition. However, autophagy that is impaired by other means has similar effects on stress granules, so it is possible that the effect of *VCP* mutations on stress granule processing occurs secondary to impaired autophagy (154).

The large number of autophagy-related genes in which mutations can cause both ALS and FTD suggests that autophagy dysfunction may be important in the pathogenesis of all etiologies of ALS-FTD. In one study, spinal cord tissue from 47 patients with ALS from a variety of etiologies, including familial and sporadic, was evaluated, and all samples had *UBQLN2* in neuronal inclusions (155). A major role for autophagy in disease pathogenesis is also consistent with the ubiquity of protein aggregates found in all cases of ALS and FTD.

5. CONCLUDING REMARKS

Recent advances in human genetics, neuroimaging, and neuropathology have dramatically enhanced our ability to understand the pathogenesis of FTLT. In parallel, there are mounting biophysical, biochemical, and cell biology results supporting the model that RNA binding proteins undergo LLPS to facilitate the assembly and disassembly of many membraneless organelles. These results support the critical role of these organelles in RNA transcription, translation, transport, localization, and degradation, and they underscore the importance of maintaining homeostasis in these membraneless organelles in neurons and glia. Furthermore, many FTLT genes have critical roles in intracellular pathways, including endolysosomal

trafficking, the formation of autophagosomes, nuclear–cytoplasmic transport, and protein quality control process. Perturbations to these pathways disrupt the homeostasis of membraneless organelles and lead to the progressive accumulation of proteins.

Looking ahead, there are many crucial unanswered questions that need to be addressed before we will fully understand the disease mechanisms. First, does the LLPS property of RNA binding proteins offer broader implications for the pathogenesis of FTL? Interestingly, one recent study shows that another FTL-related protein, tau, similar to RNA binding proteins, also is intrinsically disordered and can interact with transfer RNA to form liquid droplets (156). This exciting discovery suggests a unifying theory in which the intrinsically disordered LC domain may be a common property in human proteomes. Perturbations to the properties of these proteins can promote the initiation and progression of abnormal protein aggregate formation. Second, what are the impacts of FTL genes in neuron–glia interactions? Microglia, astroglia, and oligodendroglia have critical functions in maintaining homeostasis in the nervous system. As discussed, there is compelling evidence that loss of function in the FTL genes *C9orf72* and *GRN* has profound impacts on microglial functions. It will be important to further elucidate the underlying mechanisms of microglial dysfunction and determine whether similar aberrant activation can be detected in other glial cell types. Finally, given the increased prevalence of autoimmune disorders in FTL patients, it will be important to determine whether mutations in FTL genes may lead to broader dysfunction in the innate and adaptive immune systems.

ACKNOWLEDGMENTS

We thank our colleagues at the Memory and Aging Center at UCSF for many stimulating discussions and the center's patients and caregivers for their invaluable contributions to FTD and ALS research. This work has been supported by grants from the US National Institutes of Health (grants NS098516, AG057462, and AA027074 to E.J.H., and AG019724 and AG023501 to W.W.S.), the Departments of Veterans Affairs (grants BX001108 and BX002978 to E.J.H.), and the Tau Consortium and Muscular Dystrophy Association (to W.W.S.). E.J.H. and W.W.S. are investigators of the Bluefield Project to Cure Frontotemporal Dementia.

LITERATURE CITED

1. Miller BL. 2013 Frontotemporal Dementia New York: Oxford Univ. Press
2. Ratnavalli E, Brayne C, Dawson K, Hodges JR. 2002 The prevalence of frontotemporal dementia. *Neurology* 58:1615–21 [PubMed: 12058088]
3. Pick A 1892 Über die Beziehungen der senilen Hirnatrophie zur Aphasie. *Prag. Med. Wochenschr* 17:165–67
4. Pick A 1904 Zur Symptomatologie der linksseitigen Schläfenlappenatrophie. *Monatsschrift Psychiatr. Neurol* 16:378–88
5. Alzheimer A 1911 Über eigenartige Krankheitsfälle des späteren Alters. *Z. Gesamte Neurol. Psychiatr* 4:356–85
6. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, et al. 2011 Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain* 134:2456–77 [PubMed: 21810890]
7. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, et al. 2011 Classification of primary progressive aphasia and its variants. *Neurology* 76:1006–14 [PubMed: 21325651]
8. Boeve BF, Lang AE, Litvan I. 2003 Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. *Ann. Neurol* 54(Suppl. 5):S15–19 [PubMed: 12833363]

9. Litvan I, Mangone CA, McKee A, Verny M, Parsa A, et al. 1996 Natural history of progressive supranuclear palsy (Steele–Richardson–Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. *J. Neurol. Neurosurg. Psychiatry* 60:615–20 [PubMed: 8648326]
10. Seeley WW. 2017 Mapping neurodegenerative disease onset and progression. *Cold Spring Harb. Perspect. Biol* 9:a023622 [PubMed: 28289062]
11. Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. 2009 Neurodegenerative diseases target large-scale human brain networks. *Neuron* 62:42–52 [PubMed: 19376066]
12. Raj A, Kuceyeski A, Weiner M. 2012 A network diffusion model of disease progression in dementia. *Neuron* 73:1204–15 [PubMed: 22445347]
13. Zhou J, Gennatas ED, Kramer JH, Miller BL, Seeley WW. 2012 Predicting regional neurodegeneration from the healthy brain functional connectome. *Neuron* 73:1216–27 [PubMed: 22445348]
14. Miller ZA, Rankin KP, Graff-Radford NR, Takada LT, Sturm VE, et al. 2013 TDP-43 frontotemporal lobar degeneration and autoimmune disease. *J. Neurol. Neurosurg. Psychiatry* 84:956–62 [PubMed: 23543794]
15. Miller ZA, Sturm VE, Camsari GB, Karydas A, Yokoyama JS, et al. 2016 Increased prevalence of autoimmune disease within C9 and FTD/MND cohorts: completing the picture. *Neurol. Neuroimmunol. Neuroinflammation* 3:e301
16. Broce I, Karch CM, Wen N, Fan CC, Wang Y, et al. 2018 Immune-related genetic enrichment in frontotemporal dementia: an analysis of genome-wide association studies. *PLOS Med* 15:e1002487 [PubMed: 29315334]
17. Kao AW, McKay A, Singh PP, Brunet A, Huang EJ. 2017 Progranulin, lysosomal regulation and neurodegenerative disease. *Nat. Rev. Neurosci* 18:325–33 [PubMed: 28435163]
18. Lall D, Baloh RH. 2017 Microglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia. *J. Clin. Investig* 127:3250–58 [PubMed: 28737506]
19. Mackenzie IR, Neumann M, Baborie A, Sampathu DM, Du Plessis D, et al. 2011 A harmonized classification system for FTLTDP pathology. *Acta Neuropathol* 122:111–13 [PubMed: 21644037]
20. Forman MS, Farmer J, Johnson JK, Clark CM, Arnold SE, et al. 2006 Frontotemporal dementia: clinicopathological correlations. *Ann. Neurol* 59:952–62 [PubMed: 16718704]
21. McKee AC, Cairns NJ, Dickson DW, Folkerth RD, Keene CD, et al. 2016 The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. *Acta Neuropathol* 131:75–86 [PubMed: 26667418]
22. Rodriguez RD, Suemoto CK, Molina M, Nascimento CF, Leite RE, et al. 2016 Argyrophilic grain disease: demographics, clinical, and neuropathological features from a large autopsy study. *J. Neuropathol. Exp. Neurol* 75:628–35 [PubMed: 27283329]
23. Ahmed Z, Bigio EH, Budka H, Dickson DW, Ferrer I, et al. 2013 Globular glial tauopathies (GGT): consensus recommendations. *Acta Neuropathol* 126:537–44 [PubMed: 23995422]
24. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, et al. 2006 TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Biochem. Biophys. Res. Commun* 351:602–11 [PubMed: 17084815]
25. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, et al. 2006 Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Science* 314:130–33 [PubMed: 17023659]
26. Nag S, Yu L, Capuano AW, Wilson RS, Leurgans SE, et al. 2015 Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer disease. *Ann. Neurol* 77:942–52 [PubMed: 25707479]
27. Nelson PT, Trojanowski JQ, Abner EL, Al-Janabi OM, Jicha GA, et al. 2016 “New old pathologies”: AD, PART, and cerebral age-related TDP-43 with sclerosis (CARTS). *J. Neuropathol. Exp. Neurol* 75:482–98 [PubMed: 27209644]
28. Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, et al. 2006 Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. *Nature* 442:916–19 [PubMed: 16862116]

29. Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, et al. 2006 Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. *Nature* 442:920–24 [PubMed: 16862115]
30. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, et al. 2011 Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. *Neuron* 72:245–56 [PubMed: 21944778]
31. Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, et al. 2011 A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS–FTD. *Neuron* 72:257–68 [PubMed: 21944779]
32. Hirsch-Reinshagen V, Pottier C, Nicholson AM, Baker M, Hsiung GR, et al. 2017 Clinical and neuropathological features of ALS/FTD with TIA1 mutations. *Acta Neuropathol. Commun* 5:96 [PubMed: 29216908]
33. Mackenzie IR, Nicholson AM, Sarkar M, Messing J, Purice MD, et al. 2017 TIA1 mutations in amyotrophic lateral sclerosis and frontotemporal dementia promote phase separation and alter stress granule dynamics. *Neuron* 95:808–16.e9 [PubMed: 28817800]
34. Van Mossevelde S, van der Zee J, Gijselinck I, Engelborghs S, Sieben A, et al. 2016 Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort. *Brain* 139:452–67 [PubMed: 26674655]
35. Koriath CA, Bocchetta M, Brotherhood E, Woollacott IO, Norsworthy P, et al. 2017 The clinical, neuroanatomical, and neuropathologic phenotype of TBK1-associated frontotemporal dementia: a longitudinal case report. *Alzheimer's Dement* 6:75–81
36. Pottier C, Bieniek KF, Finch N, van de Vorst M, Baker M, et al. 2015 Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. *Acta Neuropathol* 130:77–92 [PubMed: 25943890]
37. Guinto JB, Ritson GP, Taylor JP, Forman MS. 2007 Valosin-containing protein and the pathogenesis of frontotemporal dementia associated with inclusion body myopathy. *Acta Neuropathol* 114:55–61 [PubMed: 17457594]
38. Kwiatkowski TJ Jr., Bosco DA, Leclerc AL, Tamrazian E, Vandenburg CR, et al. 2009 Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. *Science* 323:1205–8 [PubMed: 19251627]
39. Vance C, Rogelj B, Hortobagyi T, De Vos KJ, Nishimura AL, et al. 2009 Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. *Science* 323:1208–11 [PubMed: 19251628]
40. Mackenzie IRA, Neumann M. 2017 Fused in sarcoma neuropathology in neurodegenerative disease. *Cold Spring Harb. Perspect. Med* 7:a024299 [PubMed: 28096243]
41. Shang Y, Huang EJ. 2016 Mechanisms of FUS mutations in familial amyotrophic lateral sclerosis. *Brain Res* 1647:65–78 [PubMed: 27033831]
42. Huang EJ, Zhang J, Geser F, Trojanowski JQ, Strober JB, et al. 2010 Extensive FUS-immunoreactive pathology in juvenile amyotrophic lateral sclerosis with basophilic inclusions. *Brain Pathol* 20:1069–76 [PubMed: 20579074]
43. Perry DC, Brown JA, Possin KL, Datta S, Trujillo A, et al. 2017 Clinicopathological correlations in behavioural variant frontotemporal dementia. *Brain* 140:3329–45 [PubMed: 29053860]
44. Pottier C, Ravenscroft TA, Sanchez-Contreras M, Rademakers R. 2016 Genetics of FTL D: overview and what else we can expect from genetic studies. *J. Neurochem* 138(Suppl. 1):32–53 [PubMed: 27009575]
45. Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, et al. 2011 Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. *Nat. Neurosci* 14:459–68 [PubMed: 21358643]
46. Tollervey JR, Curk T, Rogelj B, Briesse M, Cereda M, et al. 2011 Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. *Nat. Neurosci* 14:452–58 [PubMed: 21358640]
47. Chou CC, Zhang Y, Umoh ME, Vaughan SW, Lorenzini I, et al. 2018 TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. *Nat. Neurosci* 21:228–39 [PubMed: 29311743]

48. Ling SC, Polymenidou M, Cleveland DW. 2013 Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. *Neuron* 79:416–38 [PubMed: 23931993]
49. Kato M, McKnight SL. 2017 A solid-state conceptualization of information transfer from gene to message to protein. *Annu. Rev. Biochem* 87:351–90 [PubMed: 29195049]
50. Schneider JW, Gao Z, Li S, Farooqi M, Tang TS, et al. 2008 Small-molecule activation of neuronal cell fate. *Nat. Chem. Biol* 4:408–10 [PubMed: 18552832]
51. Han TW, Kato M, Xie S, Wu LC, Mirzaei H, et al. 2012 Cell-free formation of RNA granules: bound RNAs identify features and components of cellular assemblies. *Cell* 149:768–79 [PubMed: 22579282]
52. Kato M, Han TW, Xie S, Shi K, Du X, et al. 2012 Cell-free formation of RNA granules: Low complexity sequence domains form dynamic fibers within hydrogels. *Cell* 149:753–67 [PubMed: 22579281]
53. Kwon I, Kato M, Xiang S, Wu L, Theodoropoulos P, et al. 2013 Phosphorylation-regulated binding of RNA polymerase II to fibrous polymers of low-complexity domains. *Cell* 155:1049–60 [PubMed: 24267890]
54. Schwartz JC, Ebmeier CC, Podell ER, Heimiller J, Taatjes DJ, Cech TR. 2012 FUS binds the CTD of RNA polymerase II and regulates its phosphorylation at Ser2. *Genes Dev* 26:2690–95 [PubMed: 23249733]
55. Schwartz JC, Wang X, Podell ER, Cech TR. 2013 RNA seeds higher-order assembly of FUS protein. *Cell Rep* 5:918–25 [PubMed: 24268778]
56. Li P, Banjade S, Cheng HC, Kim S, Chen B, et al. 2012 Phase transitions in the assembly of multivalent signalling proteins. *Nature* 483:336–40 [PubMed: 22398450]
57. Molliex A, Temirov J, Lee J, Coughlin M, Kanagaraj AP, et al. 2015 Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization. *Cell* 163:123–33 [PubMed: 26406374]
58. Patel A, Lee HO, Jawerth L, Maharana S, Jahnel M, et al. 2015 A liquid-to-solid phase transition of the ALS protein FUS accelerated by disease mutation. *Cell* 162:1066–77 [PubMed: 26317470]
59. Burke KA, Janke AM, Rhine CL, Fawzi NL. 2015 Residue-by-residue view of in vitro FUS granules that bind the C-terminal domain of RNA polymerase II. *Mol. Cell* 60:231–41 [PubMed: 26455390]
60. Lin Y, Protter DS, Rosen MK, Parker R. 2015 Formation and maturation of phase-separated liquid droplets by RNA-binding proteins. *Mol. Cell* 60:208–19 [PubMed: 26412307]
61. Alberti S, Halfmann R, King O, Kapila A, Lindquist S. 2009 A systematic survey identifies prions and illuminates sequence features of prionogenic proteins. *Cell* 137:146–58 [PubMed: 19345193]
62. Murray DT, Kato M, Lin Y, Thurber KR, Hung I, et al. 2017 Structure of FUS protein fibrils and its relevance to self-assembly and phase separation of low-complexity domains. *Cell* 171:615–27.e16 [PubMed: 28942918]
63. Deng Q, Holler CJ, Taylor G, Hudson KF, Watkins W, et al. 2014 FUS is phosphorylated by DNA-PK and accumulates in the cytoplasm after DNA damage. *J. Neurosci* 34:7802–13 [PubMed: 24899704]
64. Monahan Z, Ryan VH, Janke AM, Burke KA, Rhoads SN, et al. 2017 Phosphorylation of the FUS low-complexity domain disrupts phase separation, aggregation, and toxicity. *EMBO J* 36:2951–67 [PubMed: 28790177]
65. Feric M, Vaidya N, Harmon TS, Mitrea DM, Zhu L, et al. 2016 Coexisting liquid phases underlie nucleolar subcompartments. *Cell* 165:1686–97 [PubMed: 27212236]
66. Shin Y, Berry J, Pannucci N, Haataja MP, Toettcher JE, Brangwynne CP. 2017 Spatiotemporal control of intracellular phase transitions using light-activated optoDroplets. *Cell* 168:159–71.e14 [PubMed: 28041848]
67. Shin Y, Brangwynne CP. 2017 Liquid phase condensation in cell physiology and disease. *Science* 357:eaaf4382
68. Protter DS, Parker R. 2016 Principles and properties of stress granules. *Trends Cell Biol* 26:668–79 [PubMed: 27289443]
69. Kanai Y, Dohmae N, Hirokawa N. 2004 Kinesin transports RNA: isolation and characterization of an RNA-transporting granule. *Neuron* 43:513–25 [PubMed: 15312650]

70. Hoell JI, Larsson E, Runge S, Nusbaum JD, Duggimpudi S, et al. 2011 RNA targets of wild-type and mutant FET family proteins. *Nat. Struct. Mol. Biol* 18:1428–31 [PubMed: 22081015]
71. Ishigaki S, Masuda A, Fujioka Y, Iguchi Y, Katsuno M, et al. 2012 Position-dependent FUS–RNA interactions regulate alternative splicing events and transcriptions. *Sci. Rep* 2:529 [PubMed: 22829983]
72. Takahama K, Takada A, Tada S, Shimizu M, Sayama K, et al. 2013 Regulation of telomere length by G-quadruplex telomere DNA- and TERRA-binding protein TLS/FUS. *Chem. Biol* 20:341–50 [PubMed: 23521792]
73. Murakami T, Qamar S, Lin JQ, Schierle GS, Rees E, et al. 2015 ALS/FTD Mutation-induced phase transition of FUS liquid droplets and reversible hydrogels into irreversible hydrogels impairs RNP granule function. *Neuron* 88:678–90 [PubMed: 26526393]
74. Kim HJ, Kim NC, Wang YD, Scarborough EA, Moore J, et al. 2013 Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. *Nature* 495:467–73 [PubMed: 23455423]
75. Todd PK, Paulson HL. 2010 RNA-mediated neurodegeneration in repeat expansion disorders. *Ann. Neurol* 67:291–300 [PubMed: 20373340]
76. Donnelly CJ, Zhang PW, Pham JT, Haeusler AR, Mistry NA, et al. 2013 RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. *Neuron* 80:415–28 [PubMed: 24139042]
77. Sareen D, O'Rourke JG, Meera P, Muhammad AK, Grant S, et al. 2013 Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. *Sci. Transl. Med* 5:208ra149
78. Almeida S, Gascon E, Tran H, Chou HJ, Gendron TF, et al. 2013 Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. *Acta Neuropathol* 126:385–99 [PubMed: 23836290]
79. O'Rourke JG, Bogdanik L, Muhammad A, Gendron TF, Kim KJ, et al. 2015 C9orf72 BAC transgenic mice display typical pathologic features of ALS/FTD. *Neuron* 88:892–901 [PubMed: 26637796]
80. Peters OM, Cabrera GT, Tran H, Gendron TF, McKeon JE, et al. 2015 Human C9ORF72 hexanucleotide expansion reproduces RNA foci and dipeptide repeat proteins but not neurodegeneration in BAC transgenic mice. *Neuron* 88:902–9 [PubMed: 26637797]
81. Liu Y, Pattamatta A, Zu T, Reid T, Bardhi O, et al. 2016 C9orf72 BAC mouse model with motor deficits and neurodegenerative features of ALS/FTD. *Neuron* 90:521–34 [PubMed: 27112499]
82. Jiang J, Zhu Q, Gendron TF, Saberi S, McAlonis-Downes M, et al. 2016 Gain of toxicity from ALS/FTD-linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs. *Neuron* 90:535–50 [PubMed: 27112497]
83. Lagier-Tourenne C, Baughn M, Rigo F, Sun S, Liu P, et al. 2013 Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. *PNAS* 110:E4530–39 [PubMed: 24170860]
84. Reddy K, Zamiri B, Stanley SY, Macgregor RB Jr., Pearson CE. 2013 The disease-associated r(GGGGCC)_n repeat from the C9orf72 gene forms tract length-dependent uni- and multimolecular RNA G-quadruplex structures. *J. Biol. Chem* 288:9860–66 [PubMed: 23423380]
85. Haeusler AR, Donnelly CJ, Periz G, Simko EA, Shaw PG, et al. 2014 C9orf72 nucleotide repeat structures initiate molecular cascades of disease. *Nature* 507:195–200 [PubMed: 24598541]
86. Freibaum BD, Lu Y, Lopez-Gonzalez R, Kim NC, Almeida S, et al. 2015 GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. *Nature* 525:129–33 [PubMed: 26308899]
87. Zhang K, Donnelly CJ, Haeusler AR, Grima JC, Machamer JB, et al. 2015 The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. *Nature* 525:56–61 [PubMed: 26308891]
88. Ash PE, Bieniek KF, Gendron TF, Caulfield T, Lin WL, et al. 2013 Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. *Neuron* 77:639–46 [PubMed: 23415312]

89. Mori K, Weng SM, Arzberger T, May S, Rentzsch K, et al. 2013 The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLN/ALS. *Science* 339:1335–38 [PubMed: 23393093]
90. Mizielinska S, Gronke S, Niccoli T, Ridler CE, Clayton EL, et al. 2014 C9orf72 repeat expansions cause neurodegeneration in *Drosophila* through arginine-rich proteins. *Science* 345:1192–94 [PubMed: 25103406]
91. Chew J, Gendron TF, Prudencio M, Sasaguri H, Zhang YJ, et al. 2015 Neurodegeneration. C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. *Science* 348:1151–54 [PubMed: 25977373]
92. Vatsavayi SC, Yoon SJ, Gardner RC, Gendron TF, Vargas JN, et al. 2016 Timing and significance of pathological features in C9orf72 expansion-associated frontotemporal dementia. *Brain* 139:3202–16 [PubMed: 27797809]
93. Kwon I, Xiang S, Kato M, Wu L, Theodoropoulos P, et al. 2014 Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. *Science* 345:1139–45 [PubMed: 25081482]
94. Lee KH, Zhang P, Kim HJ, Mitrea DM, Sarkar M, et al. 2016 C9orf72 dipeptide repeats impair the assembly, dynamics, and function of membrane-less organelles. *Cell* 167:774–88.e17 [PubMed: 27768896]
95. Lin Y, Mori E, Kato M, Xiang S, Wu L, et al. 2016 Toxic PR poly-dipeptides encoded by the C9orf72 repeat expansion target LC domain polymers. *Cell* 167:789–802.e12 [PubMed: 27768897]
96. Gijssels I, Van Mossevelde S, van der Zee J, Sieben A, Engelborghs S, et al. 2016 The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter. *Mol. Psychiatry* 21:1112–24 [PubMed: 26481318]
97. Xi Z, Rainero I, Rubino E, Pinessi L, Bruni AC, et al. 2014 Hypermethylation of the CpG-island near the C9orf72 G4C2-repeat expansion in FTLN patients. *Hum. Mol. Genet* 23:5630–37 [PubMed: 24908669]
98. Xi Z, Zhang M, Bruni AC, Maletta RG, Colao R, et al. 2015 The C9orf72 repeat expansion itself is methylated in ALS and FTLN patients. *Acta Neuropathol* 129:715–27 [PubMed: 25716178]
99. Levine TP, Daniels RD, Gatta AT, Wong LH, Hayes MJ. 2013 The product of C9orf72, a gene strongly implicated in neurodegeneration, is structurally related to DENN Rab-GEFs. *Bioinformatics* 29:499–503 [PubMed: 23329412]
100. Amick J, Rocznik-Ferguson A, Ferguson SM. 2016 C9orf72 binds SMCR8, localizes to lysosomes, and regulates mTORC1 signaling. *Mol. Biol. Cell* 27:3040–51 [PubMed: 27559131]
101. Sellier C, Campanari ML, Julie Corbier xC, Gaucherot A, Kolb-Cheynel I, et al. 2016 Loss of C9ORF72 impairs autophagy and synergizes with polyQ Ataxin-2 to induce motor neuron dysfunction and cell death. *EMBO J* 35:1276–97 [PubMed: 27103069]
102. Yang M, Liang C, Swaminathan K, Herrlinger S, Lai F, et al. 2016 A C9ORF72/SMCR8-containing complex regulates ULK1 and plays a dual role in autophagy. *Sci. Adv* 2:e1601167 [PubMed: 27617292]
103. Sullivan PM, Zhou X, Robins AM, Paushter DH, Kim D, et al. 2016 The ALS/FTLN associated protein C9orf72 associates with SMCR8 and WDR41 to regulate the autophagy–lysosome pathway. *Acta Neuropathol. Commun* 4:51 [PubMed: 27193190]
104. Burberry A, Suzuki N, Wang JY, Moccia R, Mordes DA, et al. 2016 Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease. *Sci. Transl. Med* 8:347ra93
105. O'Rourke JG, Bogdanik L, Yanez A, Lall D, Wolf AJ, et al. 2016 C9orf72 is required for proper macrophage and microglial function in mice. *Science* 351:1324–29 [PubMed: 26989253]
106. Ciura S, Lattante S, Le Ber I, Latouche M, Tostivint H, et al. 2013 Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. *Ann. Neurol* 74:180–87 [PubMed: 23720273]
107. Mackenzie IR. 2007 The neuropathology and clinical phenotype of FTD with progranulin mutations. *Acta Neuropathol* 114:49–54 [PubMed: 17458552]

108. Hu F, Padukkavidana T, Vaegter CB, Brady OA, Zheng Y, et al. 2010 Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. *Neuron* 68:654–67 [PubMed: 21092856]
109. Capell A, Liebscher S, Fellerer K, Brouwers N, Willem M, et al. 2011 Rescue of progranulin deficiency associated with frontotemporal lobar degeneration by alkalizing reagents and inhibition of vacuolar ATPase. *J. Neurosci* 31:1885–94 [PubMed: 21289198]
110. Salazar DA, Butler VJ, Argouarch AR, Hsu TY, Mason A, et al. 2015 The progranulin cleavage products, granulins, exacerbate TDP-43 toxicity and increase TDP-43 levels. *J. Neurosci* 35:9315–28 [PubMed: 26109656]
111. Zhou X, Sun L, Bastos de Oliveira F, Qi X, Brown WJ, et al. 2015 Prosaposin facilitates sortilin-independent lysosomal trafficking of progranulin. *J. Cell Biol* 210:991–1002 [PubMed: 26370502]
112. Nicholson AM, Finch NA, Almeida M, Perkerson RB, van Blitterswijk M, et al. 2016 Prosaposin is a regulator of progranulin levels and oligomerization. *Nat. Commun* 7:11992 [PubMed: 27356620]
113. Kishimoto Y, Hiraiwa M, O'Brien JS. 1992 Saposins: structure, function, distribution, and molecular genetics. *J. Lipid Res* 33:1255–67 [PubMed: 1402395]
114. Tayama M, O'Brien JS, Kishimoto Y. 1992 Distribution of saposins (sphingolipid activator proteins) in tissues of lysosomal storage disease patients. *J. Mol. Neurosci* 3:171–75 [PubMed: 1389998]
115. Meyer RC, Giddens MM, Coleman BM, Hall RA. 2014 The protective role of prosaposin and its receptors in the nervous system. *Brain Res* 1585:1–12 [PubMed: 25130661]
116. Cotman SL, Karaa A, Staropoli JF, Sims KB. 2013 Neuronal ceroid lipofuscinosis: impact of recent genetic advances and expansion of the clinicopathologic spectrum. *Curr. Neurol. Neurosci. Rep* 13:366 [PubMed: 23775425]
117. Almeida MR, Macario MC, Ramos L, Baldeiras I, Ribeiro MH, Santana I. 2016 Portuguese family with the co-occurrence of frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis phenotypes due to progranulin gene mutation. *Neurobiol. Aging* 41:200e1–5
118. Smith KR, Damiano J, Franceschetti S, Carpenter S, Canafoglia L, et al. 2012 Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. *Am. J. Hum. Genet* 90:1102–7 [PubMed: 22608501]
119. Gotzl JK, Mori K, Damme M, Fellerer K, Tahirovic S, et al. 2014 Common pathobiochemical hallmarks of progranulin-associated frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis. *Acta Neuropathol* 127:845–60 [PubMed: 24619111]
120. Ward ME, Chen R, Huang HY, Ludwig C, Telpoukhovskaia M, et al. 2017 Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis. *Sci. Transl. Med* 9:eaah5642
121. Ahmed Z, Sheng H, Xu YF, Lin WL, Innes AE, et al. 2010 Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. *Am. J. Pathol* 177:311–24 [PubMed: 20522652]
122. Martens LH, Zhang J, Barmada SJ, Zhou P, Kamiya S, et al. 2012 Progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury. *J. Clin. Investig* 122:3955–59 [PubMed: 23041626]
123. Yin F, Banerjee R, Thomas B, Zhou P, Qian L, et al. 2010 Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. *J. Exp. Med* 207:117–28 [PubMed: 20026663]
124. Yin F, Dumont M, Banerjee R, Ma Y, Li H, et al. 2010 Behavioral deficits and progressive neuropathology in progranulin-deficient mice: a mouse model of frontotemporal dementia. *FASEB J* 24:4639–47 [PubMed: 20667979]
125. Klein ZA, Takahashi H, Ma M, Stagi M, Zhou M, et al. 2017 Loss of TMEM106B ameliorates lysosomal and frontotemporal dementia-related phenotypes in progranulin-deficient mice. *Neuron* 95:281–96.e6 [PubMed: 28728022]

126. Filiano AJ, Martens LH, Young AH, Warmus BA, Zhou P, et al. 2013 Dissociation of frontotemporal dementia–related deficits and neuroinflammation in progranulin haploinsufficient mice. *J. Neurosci* 33:5352–61 [PubMed: 23516300]
127. Evers BM, Rodriguez-Navas C, Tesla RJ, Prange-Kiel J, Wasser CR, et al. 2017 Lipidomic and transcriptomic basis of lysosomal dysfunction in progranulin deficiency. *Cell Rep* 20:2565–74 [PubMed: 28903038]
128. Nixon RA. 2013 The role of autophagy in neurodegenerative disease. *Nat. Med* 19:983–97 [PubMed: 23921753]
129. Aharon-Peretz J, Badarny S, Rosenbaum H, Gershoni-Baruch R. 2005 Mutations in the glucocerebrosidase gene and Parkinson disease: phenotype–genotype correlation. *Neurology* 65:1460–61 [PubMed: 16148263]
130. Mitsui J, Mizuta I, Toyoda A, Ashida R, Takahashi Y, et al. 2009 Mutations for Gaucher disease confer high susceptibility to Parkinson disease. *Arch. Neurol* 66:571–76 [PubMed: 19433656]
131. Ramirez A, Heimbach A, Grundemann J, Stiller B, Hampshire D, et al. 2006 Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. *Nat. Genet* 38:1184–91 [PubMed: 16964263]
132. Schuur M, Ikram MA, van Swieten JC, Isaacs A, Vergeer-Drop JM, et al. 2011 Cathepsin D gene and the risk of Alzheimer’s disease: a population-based study and meta-analysis. *Neurobiol. Aging* 32:1607–14 [PubMed: 19926167]
133. Nguyen AD, Nguyen TA, Zhang J, Devireddy S, Zhou P, et al. 2018 Murine knockin model for progranulin-deficient frontotemporal dementia with nonsense-mediated mRNA decay. *PNAS* 115:E2849–58 [PubMed: 29511098]
134. Rabouille C. 2017 Pathways of unconventional protein secretion. *Trends Cell Biol* 27:230–40 [PubMed: 27989656]
135. Laplante M, Sabatini DM. 2012 mTOR signaling in growth control and disease. *Cell* 149:274–93 [PubMed: 22500797]
136. Sardiello M, Palmieri M, di Ronza A, Medina DL, Valenza M, et al. 2009 A gene network regulating lysosomal biogenesis and function. *Science* 325:473–77 [PubMed: 19556463]
137. Settembre C, Di Malta C, Polito VA, Garcia Arencibia M, Vetrini F, et al. 2011 TFEB links autophagy to lysosomal biogenesis. *Science* 332:1429–33 [PubMed: 21617040]
138. Kao AW, Eisenhut RJ, Martens LH, Nakamura A, Huang A, et al. 2011 A neurodegenerative disease mutation that accelerates the clearance of apoptotic cells. *PNAS* 108:4441–46 [PubMed: 21368173]
139. Lui H, Zhang J, Makinson SR, Cahill MK, Kelley KW, et al. 2016 Progranulin deficiency promotes circuit-specific synaptic pruning by microglia via complement activation. *Cell* 165:921–35 [PubMed: 27114033]
140. Chang MC, Srinivasan K, Friedman BA, Suto E, Modrusan Z, et al. 2017 Progranulin deficiency causes impairment of autophagy and TDP-43 accumulation. *J. Exp. Med* 214:2611–28 [PubMed: 28778989]
141. Takahashi H, Klein ZA, Bhagat SM, Kaufman AC, Kostylev MA, et al. 2017 Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP network. *Acta Neuropathol* 133:785–807 [PubMed: 28070672]
142. Stephan AH, Barres BA, Stevens B. 2012 The complement system: an unexpected role in synaptic pruning during development and disease. *Annu. Rev. Neurosci* 35:369–89 [PubMed: 22715882]
143. Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, et al. 2007 The classical complement cascade mediates CNS synapse elimination. *Cell* 131:1164–78 [PubMed: 18083105]
144. Cadwell K, Debnath J. 2018 Beyond self-eating: the control of nonautophagic functions and signaling pathways by autophagy-related proteins. *J. Cell Biol* 217:813–22 [PubMed: 29237720]
145. Shaid S, Brandts CH, Serve H, Dikic I. 2013 Ubiquitination and selective autophagy. *Cell Death Differ* 20:21–30 [PubMed: 22722335]
146. Tresse E, Salomons FA, Vesa J, Bott LC, Kimonis V, et al. 2010 VCP/p97 is essential for maturation of ubiquitin-containing autophagosomes and this function is impaired by mutations that cause IBMPFD. *Autophagy* 6:217–27 [PubMed: 20104022]

147. Maruyama H, Morino H, Ito H, Izumi Y, Kato H, et al. 2010 Mutations of optineurin in amyotrophic lateral sclerosis. *Nature* 465:223–26 [PubMed: 20428114]
148. Shen WC, Li HY, Chen GC, Chern Y, Tu PH. 2015 Mutations in the ubiquitin-binding domain of OPTN/optineurin interfere with autophagy-mediated degradation of misfolded proteins by a dominant-negative mechanism. *Autophagy* 11:685–700 [PubMed: 25484089]
149. Cassel JA, Reitz AB. 2013 Ubiquilin-2 (UBQLN2) binds with high affinity to the C-terminal region of TDP-43 and modulates TDP-43 levels in H4 cells: characterization of inhibition by nucleic acids and 4-aminoquinolines. *Biochim. Biophys. Acta* 1834:964–71 [PubMed: 23541532]
150. Osaka M, Ito D, Suzuki N. 2016 Disturbance of proteasomal and autophagic protein degradation pathways by amyotrophic lateral sclerosis-linked mutations in ubiquilin 2. *Biochem. Biophys. Res. Commun* 472:324–31 [PubMed: 26944018]
151. Wu Q, Liu M, Huang C, Liu X, Huang B, et al. 2015 Pathogenic Ubqln2 gains toxic properties to induce neuron death. *Acta Neuropathol* 129:417–28 [PubMed: 25388785]
152. Rubino E, Rainero I, Chio A, Rogaeva E, Galimberti D, et al. 2012 SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Neurology* 79:1556–62 [PubMed: 22972638]
153. Buchan JR, Kolaitis RM, Taylor JP, Parker R. 2013 Eukaryotic stress granules are cleared by autophagy and Cdc48/VCP function. *Cell* 153:1461–74 [PubMed: 23791177]
154. Seguin SJ, Morelli FF, Vinet J, Amore D, De Biasi S, et al. 2014 Inhibition of autophagy, lysosome and VCP function impairs stress granule assembly. *Cell Death Differ* 21:1838–51 [PubMed: 25034784]
155. Deng HX, Chen W, Hong ST, Boycott KM, Gorrie GH, et al. 2011 Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. *Nature* 477:211–15 [PubMed: 21857683]
156. Zhang X, Lin Y, Eschmann NA, Zhou H, Rauch JN, et al. 2017 RNA stores tau reversibly in complex coacervates. *PLOS Biol* 15:e2002183 [PubMed: 28683104]

Figure 1.

Summary of the clinical syndromes, neuropathology, and genetics of FTD. The six clinical syndromes include bvFTD, svPPA, nvfPPA, FTD-MND, CBS, and PSP-RS. A small number of patients with bvFTD, svPPA, nvfPPA, or CBS have Alzheimer's disease as the underlying pathology. Based on the proteinopathy involved, the neuropathology of FTLD can be classified as FTLD-tau, FTLD-TDP, or FTLD-FUS. Genetic mutations associated with each molecular subtype are italicized. A rare subtype of FTLD (FTLD-3) has been reported in patients with mutations in the *CHMP2B* gene. The designations 3R and 4R indicate, respectively, three microtubule binding repeats and four tau repeats. Abbreviations: aFTLD-U, atypical FTLD-ubiquitin; AGD, argyrophilic grain disease; BIBD, basophilic inclusion body disease; bvFTD, behavioral variant FTD; CBD, corticobasal degeneration; CBS, corticobasal syndrome; CTE, chronic traumatic encephalopathy; FTD, frontotemporal dementia; FTD-MND, FTD with motor neuron disease; FTDP-17, familial FTD with mutations on the *MAPT* gene on chromosome 17; FTLD, frontotemporal lobar degeneration; GGT, globular glial tauopathy; MST, multisystem tauopathy; nvfPPA, nonfluent/agrammatic variant primary progressive aphasia; NIFID/NIBD, neuronal intermediate filament inclusion disease/neurofilament inclusion body disease; NOS, not otherwise specified; PSP-RS, progressive supranuclear palsy–Richardson syndrome; svPPA, semantic variant primary progressive aphasia.

Figure 2.

Neuropathology of FTLT. Subtypes of (a–c) FTLT-tau and (d–f) FTLT-TDP are distinguished by the morphology and distribution of their characteristic lesions. (a) Pick bodies in Pick's disease; (b) a tufted astrocyte in PSP; (c) an astrocytic plaque in CBD; (d) small compact or crescentic neuronal cytoplasmic inclusions and short, thin neuropil threads in FTLT-TDP type A; (e) diffuse granular or speckled neuronal cytoplasmic inclusions, with a relative paucity of neuropil threads, in FTLT-TDP type B; and (f) long, tortuous dystrophic neurites in FTLT-TDP type C. TDP-43 can be seen within the nucleus in neurons lacking inclusions, but it mislocalizes to the cytoplasm within inclusion-bearing neurons. (g) Immunohistochemical stain for FUS highlights the prominent FUS-positive staining in basophilic inclusions in the cytoplasm of spinal motor neurons in an ALS-FUS case. (h,i) Ultrastructural analyses of the same case as shown in panel g show that these inclusions (h) contain filamentous aggregates measuring 15–20 nm in diameter and (i) are immunoreactive for FUS antibody. (j) The most common subtype of FTLT-FUS is aFTLT-U, characterized by signature FUS immunoreactive vermiform intranuclear inclusions. Immunostains were performed using antibodies to (a) 3R tau, (b,c) phospho-tau (CP-13), (d–f) TDP-43, and (g,i,j) FUS. The scale bar in panel f is applicable to panels a–e. Abbreviations: aFTLT-U, atypical FTLT-ubiquitin; ALS, amyotrophic lateral sclerosis; CBD, corticobasal degeneration; FTLT, frontotemporal lobar degeneration; EM, electron microscopy; IHC,

immunohistochemistry; ImmEM, immunogold electron microscopy; PSP, progressive supranuclear palsy.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 3.

Liquid–liquid phase separation (LLPS) governs the formation of membraneless organelles. (a) Schematic representing the low-complexity (LC) domain, RNA (with relaxed and stem-loop configurations), and the RNA binding proteins FUS, TDP-43, and hnRNPA1, each containing an LC domain, RNA recognition domain, and arginine-glycine-rich motifs. (b) LLPS promotes the formation of membraneless liquid droplets or hydrogels, a process which can be facilitated by the presence of RNA and low temperatures. The metastable property of liquid droplets is critical for the assembly and disassembly of many membraneless organelles, such as RNA granules, stress granules, the nucleolus, and nuclear speckles. Under pathological conditions, liquid droplets can transition into a solid-state structure or form amyloid fibrils, which are more stable and whose formation is likely irreversible.

Figure 4.

Intracellular pathways targeted by disease pathogenesis in FTL D. The most common genetic mutation in FTL D is caused by (GGGGCC)_n hexanucleotide repeat expansion in the *C9orf72* gene. *C9orf72* mutations are known to generate RNA foci, which reside primarily in the nucleus. In addition, *C9orf72* mutations use RAN-mediated translation to generate DPRs that disrupt the nuclear pore complex and interfere with liquid droplet formation. Finally, the protein product of *C9orf72* has been detected in complex with WDR41 and SMCR8 as regulating the initiation of autophagy and the formation of autophagosomes. Several other FTL D genes, including *SQSTM1*, *UBQLN2*, *OPTN*, and *VCP*, have also been implicated in autophagy and the formation of autophagosomes. *GRN*, another major FTL D gene, encodes progranulin, a glycoprotein that can be either secreted and endocytosed or directly transported to the endolysosomal pathway where it regulates the formation, turnover, and possibly the exophagy of lysosomes. Abbreviations: DPR, dipeptide repeat; FTL D, frontotemporal lobar degeneration; MVB, multivesicular body; RAN, repeat-associated non-ATG.